Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Preliminary Q4 Revenues Up 63 Percent, Beat Estimates

NEW YORK – CareDx said on Monday that it expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.

On average, analysts are expecting Q4 revenues of $53.2 million.

CareDx said that for the three months ended Dec. 31, 2020, testing revenue is expected to be between $50.0 million and $50.2 million compared to $29.1 million in the year-ago period. CareDx provided approximately 25,100 patient results for its AlloSure and AlloMap tests, including approximately 1,100 AlloSure Heart patient results since CareDx received Medicare reimbursement for the test.

Fourth quarter product revenue is expected to be $5.9 million compared to $5.1 million a year ago, while digital and other revenue is expected to be $2.4 million compared to $1.6 million.

Preliminary revenue for the full year is expected to be between $191.9 million and $192.1 million, up about 51 percent from $127.1 million in 2019, and ahead of analysts' average expectation of $186.8 million. Full-year testing revenue is expected to be $163.3 million to $163.5 million compared to $104.6 million in 2019, while product revenue is excepted to be $19.3 million compared to $18.3 million a year ago. Digital and other revenue for 2020 is expected to be $9.3 million compared to $4.2 million in 2019.

CareDx said its preliminary cash, cash equivalents, and marketable securities totaled $224.7 million as of Dec. 31.

In Monday morning trading on the Nasdaq, shares of CareDx were down about 1 percent at $80.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.